Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as fi...
Prof Bruno Sangro - University of Navarra, Pamplona, Spain
CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as first-line treatment in aHCC ( Prof Bruno Sangro - University of Navarra, Pamplona, Spain )
15 Jul 2020
Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal aden...
Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA
Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma ( Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA )
8 Jul 2020
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into live...
Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, US...
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab ( Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, USA )
17 Jun 2020
Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for re...
Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA
Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma ( Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA )
15 Jun 2020
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Dr Katie Kelley - University of California San Francisco, San Francisco, USA
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma ( Dr Katie Kelley - University of California San Francisco, San Francisco, USA )
12 Jun 2020
Highlights from ASCO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2020 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
5 Jun 2020
The potential of KRAS inhibitors for non-small-cell lung cancer
Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany
The potential of KRAS inhibitors for non-small-cell lung cancer ( Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany )
22 Apr 2020
NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cel...
Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France
NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma ( Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France )
18 Feb 2020
Surgical treatment of cholangiocarcinoma and liver metastases
Dr. Amit Mathur, Mayo Clinic, Rochester, USA
Surgical treatment of cholangiocarcinoma and liver metastases ( Dr. Amit Mathur, Mayo Clinic, Rochester, USA )
21 Oct 2019
Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA
Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC ( Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA )
4 Oct 2019
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line...
Dr Thomas Yau - The University of Hong Kong, Hong Kong
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma ( Dr Thomas Yau - The University of Hong Kong, Hong Kong )
4 Oct 2019
Health-related quality of life for patients with metastatic pancreatic cancer: U...
Prof Eric Van Cutsem and Dr Teresa Macarulla
Health-related quality of life for patients with metastatic pancreatic cancer: Updates from ESMO 2019 ( Prof Eric Van Cutsem and Dr Teresa Macarulla )
2 Oct 2019